In this issue:
Alemtuzumab CARE-MS I 5-year follow-up
Alemtuzumab CARE-MS II 5-year follow-up
Anti-inflammatory DMT and short-term disability progression in SPMS
Longitudinal analysis of MOG-IgG in CNS inflammatory diseases
Genetic variation in the gene LRP2 increases relapse risk in MS
Prediction of individual MS treatment response
tDCS for treatment for MS-related fatigue
Safety and efficacy of cladribine tablets in RRMS
Lymphocyte levels and infection status in RRMS patients treated with daclizumab beta
Limitations in communication between MS patients and their neurologists
Please login below to download this issue (PDF)